Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TDP2 | O95551 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GALK1 | P51570 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1759000 | 1.00 | EGFR (0.35) | EGFRERBB2KDM1AIDO1KDM4E | |
| SCHEMBL391322 | 1.00 | EGFR (0.35) | EGFRERBB2KDM1AIDO1KDM4E | |
| SCHEMBL1680560 | 0.91 | EGFR (0.39) | EGFRERBB2KDM1AIDO1KDM4E | |
| SCHEMBL9985983 | 0.89 | EGFR (0.36) | EGFRERBB2KDM1AIDO1ALDH1A1 | |
| SCHEMBL1578331 | 0.88 | — | — | |
| SCHEMBL5700201 | 0.80 | EGFR (0.34) | EGFRERBB2KDM1AKDM4ETDP2 | |
| SCHEMBL2155195 | 0.79 | KDM1A (0.43) | EGFRERBB2KDM1AIDO1KDM4E | |
| SCHEMBL18980719 | 0.78 | KDM4E (0.34) | EGFRERBB2KDM1AKDM4ESLC6A4 | |
| SCHEMBL5609115 | 0.78 | KDM1A (0.33) | KDM1AIDO1KDM4EALDH1A1SLC6A4 | |
| SCHEMBL7775994 | 0.76 | KDM1A (0.38) | EGFRERBB2KDM1AIDO1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577253-B2 | 5,6-dihydrothieno[3,4-h]quinazoline compound | Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (CN) | 2026-03-17 | — | — | US | disclosed |
| WO-2025067433-A1 | COMPOUND TARGETING INTEGRIN AND USE THEREOF IN RNAI AGENT | 云合智药（苏州）生物科技有限公司 | 2025-04-03 | — | — | WO | disclosed |
| WO-2025040767-A1 | 2-(3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL)-1,3,5-TRIAZINE DERIVATIVES AS KRAS G12D INHIBITORS FOR THE TREATMENT OF CANCER | SANOFI (FR) | 2025-02-27 | — | — | WO | disclosed |
| US-20240376093-A1 | SULFOXIMINE COMPOUND AND USE THEREOF | USYNOVA PHARMACEUTICALS LTD. (CN) | 2024-11-14 | — | — | US | disclosed |
| US-20240140962-A1 | 5,6-DIHYDROTHIENO[3,4-H]QUINAZOLINE COMPOUND | Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (CN) | 2024-05-02 | — | — | US | disclosed |
| EP-4361138-A1 | SULFOXIMINE COMPOUND AND USE THEREOF | Medshine Discovery Inc. (CN) | 2024-05-01 | — | — | EP | disclosed |
| WO-2024067857-A1 | MACROCYCLIC DERIVATIVE AND USE THEREOF | 南京明德新药研发有限公司 | 2024-04-04 | — | — | WO | disclosed |
| WO-2023250431-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-4289852-A1 | 5,6-DIHYDROTHIENO[3,4-H]QUINAZOLINE COMPOUND | Medshine Discovery Inc. (CN) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023093728-A1 | BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
| EP-2049491-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2009013390-A1 | 2, 3-DIHYDROBENZO[1, 4] DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | ORION CORPORATION (FI) | 2009-01-29 | — | — | WO | disclosed |
| EP-2001885-A2 | OCTAHYDRO-PYRROLO[3,4-B]PYRROLE DERIVATIVES | Abbott Laboratories (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008019124-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007100990-A2 | OCTAHYDRO-PYRROLO[3,4-B] PYRROLE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070093480-A1 | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
| EP-1000060-A1 | NOVEL COMPOUNDS | AstraZeneca UK Limited (GB) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999002528-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1999-01-21 | — | — | WO | disclosed |
| EP-0715615-A1 | METHOD FOR PREPARING (+)-(1R)-CIS-3-OXO-2-PENTYL-1-CYCLOPENTANEACETIC ACID | FIRMENICH SA (CH) | 1996-06-12 | — | — | EP | disclosed |
| WO-1996000206-A1 | METHOD FOR PREPARING (+)-(1R)-CIS-3-OXO-2-PENTYL-1-CYCLOPENTANEACETIC ACID | FIRMENICH S.A. (CH) | 1996-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140962-A1 | 5,6-DIHYDROTHIENO[3,4-H]QUINAZOLINE COMPOUND | PLK1, AURKA, AURKC | EGFR 1829/4885ERBB2 1041/4885KDM1A 1878/4885 |
| US-20240376093-A1 | SULFOXIMINE COMPOUND AND USE THEREOF | TST, STS, SMOX | EGFR 3306/4885ERBB2 2743/4885KDM1A 2897/4885 |
| US-12577253-B2 | 5,6-dihydrothieno[3,4-h]quinazoline compound | PLK1, AURKC, BUB1 | EGFR 275/4885ERBB2 98/4885KDM1A 1379/4885 |
| US-20070093480-A1 | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | MAP3K19, MAP4K2, MAP3K1 | EGFR 569/4885ERBB2 110/4885KDM1A 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.